Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Intrasense S.A. (ALINS.PA)
Montpellier, FR
Established in 2004 and headquartered in Montpellier, France, Intrasense S.A. specializes in the global development of sophisticated software for visualizing and analyzing diverse medical imaging data, marketed under its Myrian brand. The company's offerings feature the Myrian Imaging Layer, a versatile multi-modality visualization platform tailored for professionals in the health industry. It also provides Myrian Studio, a dedicated development environment empowering innovators, industrial partners, spin-offs, and research institutions to build medical imaging applications. Furthermore, Intrasense leverages its Myrian technologies to facilitate the creation of biomarkers and artificial intelligence solutions. A key component of its product line is Myrian Clinical Apps, an extensive collection of advanced post-processing clinical applications. This portfolio encompasses specialized modules like Myrian XP-Breast, XP-Prostate, XP-Liver, XP-Mammo, XP-Lung, XP-Colon, XP-Vessel, and XP-Cardiac, alongside Myrian XL-Onco for tracking lesions. These applications, which also provide solutions for analyzing specific pathologies or organs, offer various tools for interpreting data from MRI, CT scans, conventional radiology, and nuclear imaging examinations.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.42% | +0.00% | +12.86% | -2.47% | -9.54% | +3.49% | -25.71% | -46.01% | -67.97% | -74.24% | -96.71% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Healthcare Information Services: +14.2%+31.9% ★ Q4'25: +20.7% (vs Q4'23)
-
EPS growth Medical - Healthcare Information Services: +43.1%-81.8% Q4'25: -312.1% (vs Q4'23)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%-308.4% Q4'25: -270.4% (vs Q4'23)
-
EBIT margin Medical - Healthcare Information Services: +8.8%-368.0% Q4'25: -439.6% (vs Q4'23)
-
ROIC Medical - Healthcare Information Services: +5.2%— Q4'25: +333.3% (vs Q4'23)
-
Share dilution Medical - Healthcare Information Services: -0.1%+0.5% Q4'25: +3.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×-0.05× Q4'25: -0.02× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2016 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.54M
est: 2.64M (-3.6%)
|
4.10M
est: 4.26M (-3.7%)
|
4.15M
est: 5.22M (-20.5%)
|
3.38M
est: 2.44M (+38.8%)
|
3.69M
est: 3.04M (+21.2%)
|
3.77M
est: 4.26M (-11.6%)
|
3.32M
est: 5.57M (-40.4%)
|
3.44M
est: 7.37M (-53.3%)
|
3.31M
est: 3.31B (-99.9%)
|
2.25M
est: 3.11B (-99.9%)
|
2.96M
est: 5.33B (-99.9%)
|
| EBITDA |
-1.20M
est: -1.33M (+9.6%)
|
-410.3K
est: -2.08M (+80.3%)
|
-1.67M
est: -551.3K (-202.2%)
|
-4.43M
est: -788.3K (-462.6%)
|
-1.35M
est: -1.50M (+10.0%)
|
-1.05M
est: -2.10M (+50.1%)
|
-547.0K
est: -2.44M (+77.5%)
|
-30.0K
est: -3.73M (+99.2%)
|
-2.68M
est: -1.66B (+99.8%)
|
-4.60M
est: -2.18B (+99.8%)
|
-9.24M
est: -3.74B (+99.8%)
|
| EBIT |
-2.08M
est: -1.77M (-17.3%)
|
-1.07M
est: -3.47M (+69.1%)
|
-2.61M
est: -1.45M (-80.3%)
|
-6.35M
est: -1.26M (-404.4%)
|
-2.06M
est: -2.00M (-2.6%)
|
-1.81M
est: -2.81M (+35.5%)
|
-903.0K
est: -2.25M (+59.8%)
|
-656.0K
est: -4.98M (+86.8%)
|
-3.53M
est: -2.22B (+99.8%)
|
-5.59M
est: -2.59B (+99.8%)
|
-10.91M
est: -4.44B (+99.8%)
|
| Net Income |
-1.62M
est: -35.14M (+95.4%)
|
-553.6K
est: -2.62M (+78.8%)
|
-1.84M
est: -673.8K (-172.8%)
|
-5.47M
est: -858.2K (-537.7%)
|
-1.77M
est: -9.06M (+80.5%)
|
-1.51M
est: -532.7K (-183.2%)
|
-912.0K
est: -2.02M (+54.9%)
|
-704.0K
est: -9.7K (-7,152.5%)
|
-3.58M
est: -3.67M (+2.6%)
|
-5.66M
est: -4.22M (-34.1%)
|
-10.81M
est: -2.64M (-310.0%)
|
| SGA |
—
est: -108.7K (+100.0%)
|
—
est: -175.7K (+100.0%)
|
606.1K
est: 4.15M (-85.4%)
|
120.0K
est: 1.91M (-93.7%)
|
173.8K
est: -123.0K (+241.3%)
|
424.5K
est: 3.42M (-87.6%)
|
880.0K
est: 3.26M (-73.0%)
|
-724.6K
est: -305.3K (-137.3%)
|
84.0K
est: -136.18M (+100.1%)
|
-701.0K
est: 3.25B (-100.0%)
|
15.50M
est: 5.58B (-99.7%)
|
| EPS |
-0.73
est: -0.67 (-9.0%)
|
-0.17
est: -0.15 (-10.0%)
|
-0.55
est: -0.66 (+16.6%)
|
-1.30
est: -0.82 (-57.8%)
|
-0.17
est: -0.18 (+2.9%)
|
-0.08
est: -0.01 (-672.8%)
|
-0.04
est: 0.00 (-2,944.3%)
|
-0.03
est: 0.00 (-15,114.0%)
|
-0.07
est: -0.07 (+0.4%)
|
-0.11
est: -0.08 (-37.5%)
|
-0.20
est: -0.05 (-300.0%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Stephen Armand | Chief Executive Officer | 196.8K | male |
| Fanny Louvet-de Verchere | Chief Product & Marketing Officer | — | — |
| Jerome Thiebaud | Chief Business Officer | — | — |
| Marion Peureux | Human Resources Manager | — | — |
| Pierre Voiriot | Chief Technical Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALINS.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
